Document is current

Article History

Received: 24 January 2025

Accepted: 19 March 2025

First Online: 14 April 2025

Declarations

:

: The study was conducted in accordance with the Declaration of Helsinki and received approval from the ethics committee of the University Hospital Bonn, Germany (reference number: 097/18). Written informed consent was obtained from every patient prior to inclusion in the study.

: Not applicable.

: JHT: Bayer (Consulting, Funding, Honoraria); Novartis (Recipient, Honoraria), Roche (Funding), Okko (Consulting)SMP, LCB, VSS noneJJ: NoneKR: NoneFGH: Acucela (Consulting, Funding), Allergan (Funding), Apellis (Consulting, Funding), Bayer (Consulting, Funding), Boehringer-Ingelheim (Consulting), Bioeq/ Formycon (F,C), CenterVue (Funding), Ellex (Funding), Roche/Genentech (Consulting, Funding), Geuder (Consulting, Funding), Graybug (Consulting), Gyroscope (Consulting), Heidelberg Engineering (Consulting, Funding), IvericBio (Consulting, Funding), Kanghong (Consulting, Funding), LinBioscience (Consulting), NightStarX (Funding), Novartis (Consulting, Funding), Optos (Funding), Oxurion (Consulting), Pixium Vision (Consulting, Funding), Oxurion (Consulting), Stealth BioTherapeutics (Consulting), Zeiss (Funding, Consulting)TA: Novartis (Speaker honorarium), Astellas (Speaker honorarium, Advisory board), Apellis (Speaker honorarium), Heidelberg Engineering (Speaker honorarium), Bayer (Speaker honorarium), Roche (Speaker honorarium, Travel reimbursement), Nidek (Research funding, speaker honorarium)MWMW: Baxter Healthcare Corporation: research grant, Bayer AG: honoraria, glaucare GmbH: consultant, owner , Novartis Pharma GmbH: honoraria, grant, DigiSight Technologies: travel grant, D-EYE Srl: imaging devices, Heine Optotechnik GmbH: research funding, imaging devices, travel reimbursements, consultant; Eyenuk, Inc: free trial analysis; ASKIN & CO GmbH: travel reimbursement, honoraria; Berlin-Chemie AG: grant, travel reimbursements; Imaging devices were provided by Heidelberg Engineering, Optos, Carl Zeiss Meditec, and CenterVueRPF: Bayer (Consultant), Ellex (Consultant), Novartis (Consultant), Novartis (Funding), Ophtea (Consultant), Alimera (Consultant), Santhera (Consultant), Roche/Genentech (Consultant), ICare (formerly CentreVue) (Funding), Zeiss (Funding)